GenVec Inc. (Nasdaq: GNVC) entered an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting. Shares of the biopharmaceutical leaped $3.82 to close at $8.79.
